Dr Kola Tytler MBBS CertHE MBA MSt MRCGPClinical Lead • iatroX
Are there any additional biomarkers that should be considered alongside KELIM to optimize treatment planning in BRCA-negative, HRD-negative ovarian cancers?
Key References
- SmPC: Lynparza 100mg film-coated tablets
- SmPC: Lynparza 150 mg film-coated tablets
- NICE CKS: Ovarian cancer
- NICE CG122: Ovarian cancer: recognition and initial management
- NICE NG241: Ovarian cancer: identifying and managing familial and genetic risk
- NICE NG122: Lung cancer: diagnosis and management
- NICE CKS: Gynaecological cancers - recognition and referral
- (Thorel et al., 2025): Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical response.
- (Gasperoni et al., N/A): Progression-Free Survival with PARP Inhibitors According to Clinical Risk in Patients with Ovarian Cancer: An Indirect Comparison Using Reconstructed Data
- (Su et al., 2025): Pretreatment circulating tumor DNA and tissue genomic profiling concordance in ovarian cancer: a prospective observational study of influencing factors and clinical implications.